https://www.selleckchem.com/pr....oducts/dibutyryl-cam
vel selection.Background Prior studies investigated regulatory actions that reflected a negative impact on drug risks. We aimed to evaluate occurrence of regulatory actions that reflected a negative or positive impact on benefits or risks, as well as relations between them.Research design and methods We followed EMA-approved innovative drugs from approval (2009-201 until July 2020 or withdrawal to identify regulatory actions. We assessed these for impact on benefits or risks and relations between actions. Additional
Мне нравится
Комментарий
Перепост
